BIIBD logo

Biogen BASE:BIIBD Stock Report

Last Price

US$11.45

Market Cap

US$21.7b

7D

-3.0%

1Y

-52.1%

Updated

25 Dec, 2024

Data

Company Financials +

Biogen Inc.

BASE:BIIBD Stock Report

Market Cap: US$21.7b

BIIBD Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More details

BIIBD fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 72.2% below our estimate of its fair value

Earnings are forecast to grow 13.57% per year

Earnings grew by 10.5% over the past year

Risk Analysis

Volatile share price over the past 3 months compared to the AR market


My Notes

Capture your thoughts, links and company narrative

Biogen Inc. Competitors

United Therapeutics

NasdaqGS:UTHR

US$16.1b

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$12.7b

Neurocrine Biosciences

NasdaqGS:NBIX

US$13.8b

Price History & Performance

Summary of share price highs, lows and changes for Biogen
Historical stock prices
Current Share PriceUS$11.45
52 Week HighUS$30.50
52 Week LowUS$11.40
Beta-0.081
1 Month Change-14.23%
3 Month Change-23.67%
1 Year Change-52.09%
3 Year Change-38.27%
5 Year Changen/a
Change since IPO-57.90%

Recent News & Updates

Recent updates

Shareholder Returns

BIIBDAR BiotechsAR Market
7D-3.0%0%0%
1Y-52.1%0%0%

Return vs Industry: BIIBD underperformed the AR Biotechs industry which returned -2% over the past year.

Return vs Market: BIIBD underperformed the AR Market which returned 140.6% over the past year.

Price Volatility

Is BIIBD's price volatile compared to industry and market?
BIIBD volatility
BIIBD Average Weekly Movement8.3%
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in AR Market0%
10% least volatile stocks in AR Market0%

Stable Share Price: BIIBD's share price has been volatile over the past 3 months compared to the AR market.

Volatility Over Time: Insufficient data to determine BIIBD's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19787,570Chris Viehbacherwww.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIBD fundamental statistics
Market capUS$21.72b
Earnings (TTM)US$1.62b
Revenue (TTM)US$9.61b

13.4x

P/E Ratio

2.3x

P/S Ratio

Is BIIBD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIIBD income statement (TTM)
RevenueUS$9.61b
Cost of RevenueUS$2.35b
Gross ProfitUS$7.26b
Other ExpensesUS$5.65b
EarningsUS$1.62b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)11.08
Gross Margin75.59%
Net Profit Margin16.81%
Debt/Equity Ratio38.5%

How did BIIBD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biogen Inc. is covered by 74 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Steven ChesneyAtlantic Equities LLP
Brian SkorneyBaird